Presentation Type: Poster
Abstract: Personalize medicine sometimes referred to as precision or individualized medicine is an emerging field of medical treatment base on molecular individual characteristics of each patient. Personalize medicine aims to identify molecular abnormalities that could act as therapeutic targets and genomic alterations causes to nonresponsive to conventional drug effect or treatment resistance. Breast cancer represents tremendously complex in its molecular pathogenesis, natural history, and biology with highly variable clinical behaviors and disparate responses to therapy. Despite the important results of research to date, breast cancer remains an incurable disease; therefore ongoing studies are evaluating the clinical benefits of personalized medicine in breast cancer. Studies have shown differences in genes that code for drug-metabolizing enzymes, drug transporters or drug targets. The majority of patients have at least one DNA variation in the enzymes that metabolize half of the most commonly prescribed medicines. The genotyping of these enzymes has produced improved dosing of drugs for disease as well as cancer. This has helped patients avoid harmful side effects, adverse drug interactions, or ineffective treatment. Breast cancer clinically has subdivided as hormone receptor positive, HER2 positive and triplenegative breast cancer, to guide therapeutic interventions. In breast cancer one of the earliest and most common examples of personalized medicine came in Herceptin® (trastuzumab) and Tykerb® (lapatinib) which are the most successful cancer therapeutics. About 30% of patients with breast cancer have HER2 over-expresses, which is not responsive to standard therapy. For this patient, trastuzumab with chemotherapy can reduce the recurrence of a tumor by 52 percent in comparison to chemotherapy alone.